Human adult spermatogonial stem cells for autologous cardiovascular tissue engineering by Heye, Pascal
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2011
Human adult spermatogonial stem cells for autologous cardiovascular tissue
engineering
Heye, Pascal
Abstract: Unbekannt
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-72650
Originally published at:
Heye, Pascal. Human adult spermatogonial stem cells for autologous cardiovascular tissue engineering.
2011, University of Zurich, Faculty of Medicine.
UniversitätsSpital Zürich 
Klinik für Herz- und Gefässchirurgie 
Abteilung Regenerative Medizin 
Leiter: Prof. Dr. med. Dr. rer. nat. S. P. Hoerstrup 
 
 
Arbeit unter Leitung von Dr. Dr. Dörthe Schmidt 
 
 
Human Adult Spermatogonial Stem Cells 
for Autologous Cardiovascular Tissue Engineering 
 
 
 
INAUGURAL-DISSERTATION 
zur Erlangung der Doktorwürde der Medizinischen Fakultät 
der Universität Zürich  
 
 
 
vorgelegt von 
Pascal Alexander Heye 
aus Fürstentum Liechtenstein 
 
 
 
Genehmigt auf Antrag von Prof. Dr. med. Dr. rer. nat. S. P. Hoerstrup 
Zürich 2011 
 
 - 2 -
Table of Contents  
 
1. Abstract         4  
 
2. Introduction         7 
2.1 Tissue engineering       7 
2.2 Adult spermatogonial stem cells     8 
2.3 Spermatogonial stem cells in tissue engineering  9 
2.4 Study outline & hypothesis      10 
 
3. Background: Experiences with adult spermatogonial    
stem cells isolated from mouse or rat testis tissue   11 
3.1 Isolation         11 
3.2 Purification with MACS sorting     11 
3.3 FACS characterization      11 
3.4 Culture         12 
 
4. Materials and methods       13 
4.1 Patients         13 
4.2 Isolation of the tissue and the cells    13 
4.3 MACS - Magnetically activated cell sorting   15 
4.4 FACS - Fluorescent activated cell sorting   16 
4.5 Media          17 
 4.5.1 Culture medium      17 
 4.5.2 Differentiation medium     19 
 
 
 
 
 - 3 -
4.6 Staining         21 
4.6.1 Adipocytes       21 
4.6.2 Osteoblasts       21 
4.6.3 Endothelial cells      22 
4.6.4 Myocytes       23 
 
5. Results         24 
5.1 Isolation         24 
5.2 MACS - Magnetically activated cell sorting   25 
5.3 FACS - Fluorescent activated cell sorting   26 
5.4 Culture         29 
5.5 Differentiation and staining      33 
 
6. Discussion         37 
6.1 Discussion of the results      37 
6.1.1 Isolation       37 
6.1.2 MACS - Magnetically activated cell sorting  38 
6.1.3 FACS - Fluorescent activated cell sorting  39 
6.1.4 Culture       39 
6.1.5 Differentiation and staining    39 
6.2 Discussion of the subject matter     40 
6.3 Outlook         43 
 
7. References         45 
 
8. Acknowledgements       54 
 
9. Curriculum Vitae        55 
 
 - 4 -
1 Abstract 
 
Background 
This work investigates the availability of pluripotent adult spermatogonial 
stem cells in human testis tissue. These cells may play an important role in 
tissue engineering and regenerative medicine applications and serve as 
autologous adult stem cells, offering an alternative to embryonic stem cells 
and thereby overcoming the ethical controversy of these cells. 
To date testis derived pluripotent adult stem cells have only been isolated 
from mouse and rat tissue (1, 3, 5, 6, 10, 11, 13, 14, 17-21, 23, 25). These 
investigations report an isolation of the cells with the aid of collagenase, 
followed by purification with magnetically activated cell sorting most efficiently 
for CD 90 and a cell characterisation with fluorescent activated cell sorting 
with a number of antigens including CD 49f and CD 29. Cultures of the cell 
populations were established most efficiently with media including growth 
factors such as GDNF, bFGF, as well as EGF and LIF. The authors described 
that a maintenance of the cells was possible, however not an expansion of 
the generated tissues. 
 
Materials and methods 
Here, human tissues were obtained by subcapsular orchiectomy or testis 
biopsies, before they underwent enzymatic digestion with collagenase, 
followed by sorting of the cells with Magnetically Activated Cell Sorting 
(MACS) for the following antibodies.  
Cells were categorized as CD 90 negative and positive, of which latter ones 
were subsequently cultured in the first investigations in different culture 
media, including EBM-2, DMEM with 10% FBS  or α MEM with IGF, bFGF 
and GDNF, in order to search for the best compatible culture medium for 
testis derived human adult spermatogonial stem cells.  
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Furthermore CD 90 positive cells were differentiated into muscle cells, 
endothelial cells, adipocytes and osteoblasts, placing them into the 
designated differentiating media respectively. 
For proof of pluripotent like characteristics, the CD 90 positive cells were 
analysed by Fluorescent Activated Cell Sorting (FACS), investigating the 
expression of CD 49f (Integrin α6) and CD 29 (Integrin β1). 
The differentiated cell lines were microscopically analysed by 
immunofluorescence using Thrombomodulin, von-Willebrandt Factor and 
Phalloidin primary antibodies for endothelial cells and α Actinin, EH-
Myomesin and Phalloidin primary antibodies for myocyte cells or simple dye 
staining including Oil Red O for osteoblasts and Alizarin Red for adipocytes. 
 
Results 
The FACS analysis revealed that the isolated cells which were previously 
sorted by MACS for CD 90 surface antibodies, expressed CD 29 (Integrin β1) 
in co-expression of CD 49f (Integrin α6). 
The isolated cells could be differentiated into the destined cell lines such as 
muscle cells, endothelial cells, adipocytes and osteoblasts, using the 
appropriate medium. 
This could be confirmed by immunofluorescent microscopy, which showed 
positive expression of von-Willebrandt Factor, Thrombomodulin and 
Phalloidin in endothelial cells as well as α Actinin, EH-Myomesin and 
Phalloidin in myocytes and Oil Red O for Osteoblasts and Alizarin Red for 
adipocytes. 
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Discussion 
As these cells have not been isolated before from human testis tissue, 
materials and methods in order to isolate, sort, differentiate and characterize 
these cells had to be established in this work.  
One of the barriers was the isolation of cells from the solid testis tissue. More 
difficulties were experienced to digest the tissue, the older the patients were.  
This was paralleled by the differentiation potential of the cells probably 
decreasing with age of the patients, as fewer cells could be differentiated into 
the desired tissue, comparing old specimens to younger ones. 
It should be investigated, whether, if at all this procedure could go into clinical 
application, the isolation of the testicular derived stem cells should be 
conducted at a young age by diagnostic biopsies. 
It could not clearly be shown, which antibody was the most effective for 
MACS sorting. In mouse tissue, CD 90 was used as the standard marker (3, 
11, 13, 14), however in this study CD 29 (Integrin β1) and CD 49f (Integrin 
α6) were shown to be comparable. 
The lack of an unambiguous cell marker also leads to an anaculture, from 
which it is not certain to derive stem cells, as it would in single cell clones.  
Cells could be differentiated successfully, however efficient expansion of 
tissue, as it would be required in tissue engineering, did not occur. 
After all, this data suggests the potential of a population of pluripotent like 
stem cells in human adult testicular tissue and might be a further step 
towards cell based autologous regenerative medicine and tissue engineering. 
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2 Introduction 
2.1 Tissue engineering 
 
Tissue engineering comprises the use of living cells for the development of 
new tissues for improvement or replacement of defective tissues and organs, 
for example blood vessels, heart valves or bladder tissue. 
This biotechnological field becomes especially useful in surgery involving the 
implantation of extrinsic or artificial implants, where the most important 
factors for success of the implant are the functionality and adaptability of the 
implant, as well as the immunological compatibility. 
Taken cardiac valve replacement surgery as an example, options given are 
biological tissues (e.g. porcine heart valve) or artificial valves. Biological 
valves do not induce drastic rejection reactions against foreign bodies, e.g. 
activation of blood clotting, as artificial valves might do and therefore do not 
need anticoagulation therapy compared with artificial valves. However 
biological valves degenerate and commonly need replacement after ten 
years. This is just one example to show that organ replacement as well as 
transplant surgery bear many risks and are not yet sufficiently satisfactory. 
Tissue engineering could overcome these limitations. With tissues developed 
from autologous cells from patients, the problem of immunological reactions 
could be depleted. There would be no shortage in donor organs for transplant 
patients and the quality of human tissue would be more efficient than that of 
e.g. porcine tissues. Engineering steps include the isolation of stem cells by 
biopsies from tissues containing stem cells, purification and proliferation of 
the isolated cells and finally seeding these cells on a graft in order to grow 
them into the desired shape and structure. 
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2.2 Adult spermatogonial stem cells 
 
Stem cells line up in the very first front of cellular differentiation. All cells in 
grown tissues are to their speciality differentiated stem cells. 
Pluripotent stem cells are capable of differentiating into cells of all three germ 
layers, i.e. forming endoderm, mesoderm and ectoderm. They are rarely 
found in human adult tissue and if so, only very few in number. 
Multipotent progenitor cells in contrast are only capable of differentiating into 
different cell types belonging to just one cell lineage, for example different 
types of blood cells belonging to the mesodermal blood cell lineage. These 
cells are amply found in bone marrow, blood or skin tissue as well as other 
organs. 
 
Pluripotent stem cells have been proven to be present in adult mouse testis 
tissue (1, 3, 5, 6, 10, 11, 13, 14, 17-21, 23, 25). These cells have not yet 
committed to differentiation, and still posses the capability to develop into any 
kind of tissue; in their foreseen manner in testis into spermatogonial, later 
developing into gametes and further more into spermatozoa and for that 
reason are called adult spermatogonial stem cells. 
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2.3 Adult spermatogonial stem cells in tissue engineering 
 
So far, one of the concepts of tissue engineering includes the isolation of 
embryonic stem cells and to induce them to differentiate into the wanted type 
of tissue.  
However the controversial discussion about embryonically derived stem cells 
is present. Ethical problems such as materialisation of an unborn human 
prohibit or limit the use of embryonic stem cells. 
 
Adult spermatogonial stem cells could mark a critical change in this issue, 
because being adult stem cells, there is no reason for ethical compunction 
compared to embryonic stem cells. 
A further issue is that allogenic embryonic stem cells own certain 
immunological characteristics which could cause rejection when transplanted. 
With spermatogonial stem cells being autologously applied, i.e. donor and 
recipient is the same person, immunological rejection can be ruled out. 
Furthermore, spermatogonial stem cells seem to possess a great advantage 
because they can easily be biopsized with no greater harm to the testicular 
tissue, cryoconserved and in the case of need be engineered for elderly male 
patients, when it comes to tissue or organ replacements, such as heart valve 
disease. 
 
For example these cells could be used in tissue engineering, generating 
endothelial cells from them, from which blood vessels could be constructed. 
Or when being explanted prior to a spermatogenesis harmful treatment, these 
cells could be re-implanted after the treatment and thereby induce new 
spermatogenesis in the male testis. 
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2.4 Study outline 
In this study the possibility of isolation of pluripotent like stem cells from 
human adult testicular tissue was examined, followed by the investigation of 
the feasibility of the testicular tissue digestion. The sorting of the cells was 
analyzed by Magnetically Activated Cell Sorting (MACS) before the cells were 
characterized for their antigens by Fluorescent Activated Cell Sorting (FACS). 
A further step of this research was the assay for culture of the presumable 
adult spermatogonial stem cells and the determination of their differentiation 
potential by differentiating the obtained cells into cells of the three germ 
layers. 
 
Hypothesis 
• Adult human spermatogonial stem cells, exhibiting pluripotent like 
character, can be isolated from adult human testicular tissue 
• Pluripotent like adult human spermatogonial stem cells can be sorted 
by MACS using CD 90 
• Pluripotent like adult human spermatogonial stem cells can be 
characterized by FACS using CD 29 and CD 49f 
• Pluripotent like adult human spermatogonial stem cells can be cultured 
and expanded 
• Pluripotent like adult human spermatogonial stem cells can be 
differentiated into cells of all the three germ layers, i.e. endoderm, 
mesoderm and ectoderm. 
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3 Background: Experiences with adult spermatogonial stem cells 
isolated from mouse or rat testis tissue 
 
Up to date, the successful isolation of spermatogonial stem cells had only 
been shown for samples collected from mouse and rat tissue (1, 3, 5, 6, 10, 
11, 13, 14, 17-21, 23, 25). The different steps are summarized as follows. 
 
3.1 Isolation of spermatogonial stem cells from mouse tissue 
Testes were surgically removed from mice, the tunica was removed and 
the tissue was transferred into tubes containing digestion medium, 
consisting of 0.5 mg/ml collagenase type IV and 0.25 mg/ml trypsin. 
Testes were digested for 15 minutes at 33°C to dissociate tubules. (1, 3, 
6, 11, 13, 17-21, 23) 
 
3.2 Purification of the spermatogonial stem cell population with MACS sorting 
Purification was achieved with magnetically activated cell sorting with 
different antigens, most efficiently CD 90. (3, 11, 13, 14) 
 
3.3 FACS characterization of spermatogonial stem cells 
The isolated cells have been characterized by their common surface 
antigen expressions being investigated by fluorescent activated cell 
sorting (1, 3, 4, 9-11, 13, 14).  
The most promising antigens used were CD90+, CD34-, CD9+, CD49f+, 
CD29+, CD24+, CD117-, MHC1-. 
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3.4 Culture of murine spermatogonial stem cells 
The authors of multiple papers describe, that the maintenance, but only 
modest expansion of the spermatogonial stem cell population was 
possible (17, 19, 21, 23).  
Furthermore it was reported that the probable pluripotent stem cell like cell 
population could be cultured most efficiently when the medium was 
supplemented with glial cell line derived neurotrophic factor (GDNF), while 
maintaining their stem cell like character. This effect could be observed at 
concentration of GDNF at 100ng/ml, but not for only 10ng/ml (23). 
Others found, that the breakthrough for maintaining the cells in culture 
came, when they included GFRα1 and bFGF to the culture medium 
containing GDNF, achieving expansions of the cell culture in the short 
term.  When only two of these growth factors were added, only a slight 
increase in cell proliferation was observed, however it was increased when 
using a combination of all these three additives (19). This was confirmed 
by other groups, using concentration of 1ng/ml of bFGF and 40ng/ml of 
human GDNF (17). Another interesting finding was that cells could be best 
maintained when the medium was serum free (17). This was confirmed by 
another group, even stating, that FBS was detrimental to the expansion of 
spermatogonial stem cells, causing a reduction of up to 60% of the activity 
of these cells (19). One group using 10% FBS in combination with α MEM 
medium could report an expansion of the pluripotent stem cells, and 
presented, that growth factors like LIF, bFGF and IGF-1 appeared to have 
a more negative than positive effect on spermatogonial stem cell 
maintenance in vitro (17). This statement seems arguable, as some 
researchers achieved spermatogonial stem cell proliferation, using glial 
cell line-derived neurotrophic factor (GDNF), epidermal growth factor 
(EGF), basic fibroblast growth factor (bFGF) and leukaemia inhibitory 
factor (LIF) (19, 21, 23, 25). 
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4 Materials and methods 
 
4.1 Patients 
Samples were obtained from eight patients in total, of which all were on 
surgical treatment for prostate cancer (n=7) or testicular torsion (n=1). The 
patients’ age ranged from 21 to 83 years, in average 58.9 years. All patients 
were informed about the study and the voluntary donation of testicular tissue 
and signed an informed consent. The study had been approved by the ethics 
committee of the UniversitätsSpital Zürich, Switzerland (Ref.Nr. StV. 32-
2008). 
 
4.2 Isolation of the tissue 
Donor testis tissue was collected by subcapsular orchiectomy in patients with 
prostate cancer and by testis biopsy in patients with testicular torsion. 
After the surgical explantation, the tissue was collected and transported in 
DMEM (Dulbecco’s Modified Eagle Medium, Invitrogen, Paisley, UK) medium 
without any supplements. 
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Isolation of the cells from the tissue 
The testicular tissue in one piece, was placed on the bottom of a Petri dish 
and frazzled by simple mechanical dissociation with scalpel and forceps, in 
order to pulpify the tissue. The product then underwent enzymatic digestion 
with collagenase A (Roche Diagnostics GmbH, Mannheim, Germany),         
20 mg/ml DMEM medium (Dulbecco’s Modified Eagle Medium, Invitrogen, 
Paisley, UK) (serum free), for 60 minutes at 37°C. To stop the enzymatic 
reaction, DMEM medium containing fetal bovine serum (Gibson, Nitrogen, 
Paisley, UK) was added, followed by resuspension of the mixture. 
Whenever the connective tissue could not well enough be digested, a 500µm 
mash was used, to separate the dissociated cells from the rest of the 
connective tissue. The product was then centrifuged for 10 minutes at 1500 
rpm (at 20°C) before the supernatant was discarded and the remaining cell 
pellet used, for further investigation. 
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4.3 MACS – Magnetically Activated Cell Sorting 
Labelling cells with antibodies: 
The cell pellet was resuspended with 90 µl PBS (Phosphate buffered saline, 
Kantonsapotheke Zürich, Switzerland) buffer. 10 µl of FITC (Fluorescein 
isothiocyanate) labelled antibodies for CD 90 (Abcam, Cambridge, UK) were 
added, following incubation for 10 minutes at 4°C.  
In another approach 10 µl of FITC (Fluorescein isothiocyanate) labelled 
antibodies for HLA-ABC (Immunotools GmbH, Friesoythe, Germany) were 
added, following incubation for 10 minutes at 4°C. 
2 ml of PBS buffer were supplemented and the mixture was centrifuged for 10 
minutes at 1500 rpm. Afterwards the supernatant was discarded. 
Then the cell pellet was resuspended with 90 µl buffer and additionally 10 µl 
of anti-FITC labelled magnetic beads (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany). Incubation then followed for 15 minutes at 4°C. 
For another time, the mixture was diluted with 2 ml PBS buffer and then 
centrifuged for 10 minutes at 1500 rpm. After the final discard of the 
supernatant, cells were resuspended in 500 µl buffer. 
A MACS syringe was fixed onto a provided magnet (Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany), attaching to the according metal plate. A 
falcon tube, 15 ml, was placed under the syringe, for collection of the cells, 
before 500 µl of buffer were placed into the MACS syringe, the liquid dripping 
into the provided tube below. Once it had run through completely, the 500 µl 
cell suspension prepared earlier was given into the syringe. After the syringe 
was emptied and the liquid collected in the same tube below, it was washed 
three times with 500 µl buffer each. The collected cells in the tube were then 
negatively labelled cells. 
For the collection of the positive cells, the syringe was taken out of the 
magnet, filled up with 1000 µl PBS buffer, closed with the provided plunger 
and emptied into a separate tube.  
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4.4 FACS – Fluorescent Activated Cell Sorting 
At first, cells were counted, using a Neubauser slide. 
The cells in a suspension were then split into polystyrene tubes, one each for 
a different antibody to be investigated, at least 100.000 cells for each. In this 
case, CD 29 and CD 49f surface markers were to be investigated and with 
that, IgG1 and IgG2a respectively as positive controls. 
The tubes were centrifuged for 10 minutes at 1500 rpm, following discard of 
the supernatant and a resuspension with 2 ml PBS buffer each and another 
centrifugation for 10 minutes at 1500 rpm. 
After discarding the supernatant, 1 µl of FITC labelled antibody (Immunotools 
GmbH, Friesoythe, Germany) was added to each tube for every 100.000 cells 
– provide a 1 µl of antibody dilution in 100 µl PBS buffer. 
 Incubation was done for 30 minutes at 4°C. The mixture was then 
resuspended with 2 ml PBS buffer, following centrifugation for 10 minutes at 
1500 rpm and the supernatant was discarded. 1 ml PBS was added again to 
the remaining cell pellet and resuspended, following storage of the tubes on 
ice, until FACS analysis was conducted with FACScan (Becton Dickinson 
Biosciences, San Jose, USA). 
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4.5 Media 
4.5.1 Culture medium: 
For the investigation which culture medium was most suitable for culture of 
human adult testicular derived stem cells, the cells were isolated and sorted, 
according to the MACS protocol described previously and then cultured in 
different culture media including different combinations of supplements. 
The obtained cells were cultured in the following different media in 12 well 
plates with each well containing 1.5 ml medium and renewal of the medium 
every three days. The cultures were passaged when the cells became 
confluent (using Trypsin EDTA, Gibco, Invitrogen, Paisley, UK). 
The cells were inspected under a phase contrast microscope (Carl Zeiss AG, 
Feldbach, Germany). 
 
The following media were tested: 
(a)   
  
  
*1Dulbecco’s Modified Eagle Medium, Invitrogen, Paisley, UK  
 *2Fetal Bovine Serum, Gibco, Invitrogen, Paisley, UK 
 
(b)    
  
  
  
  
*1Non Essential Media, Gibco, Invitrogen, Paisley, UK  
*2Insulin-like growth factor, Immunotools GmbH, Friesoythe, Germany  
 *3Basic fibroblast growth factor, Immunotools GmbH, Germany 
 *4Glial derived neurotrophic factor, Immunotools GmbH, Germany 
DMEM*1  
FBS*2 10ml/100ml 
αMEM*1  
IGF*2 1.5µg/100ml 
bFGF*3 0.1µg/100ml 
GDNF*4 0.4µg/100ml 
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(c)   
  
  
  
  
  
  
*1Endothelial basal medium, Lonza, Walkerville, USA  
Supplements provided by the supplier in combination with the medium 
*2Fetal Bovine Serum, Lonza, Walkerville, USA 
*3Fibroblast growth factor, Lonza, Walkerville, USA 
*4Endothelial growth factor, Lonza, Walkerville, USA 
*5Gentamycin, Lonza, Walkerville, USA 
*6Insulin-like growth factor, Lonza, Walkerville, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EBM-2*1  
FBS*2 2ml/100ml 
FGF*3 0.1ml/100ml 
EGF*4 0.1ml/100ml 
GM*5 0.1ml/100ml 
IGF*6 0.1ml/100ml 
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4.5.2 Differentiation medium: 
The differentiation potential of the CD 90 positive cells, was investigated, 
using differentiation media and followed by staining after four to six weeks of 
culture. 
 
Endothelial cell differentiation (26):   
 
 
 
 
Osteoblast cell differentiation (26, 27, 30):   
 
  
  
  
  
  
*1,2,3Sigma Aldrich, Germany 
 
Adipocyte cell differentiation (26, 27): 
  
  
  
  
  
  
 
 
*1,2,3Sigma Aldrich, Germany 
EBM-2  
FBS 20ml/100ml 
α MEM  
FBS 10ml/100ml 
Ascorbic Acid*1 50 µg/ml 
b-glycerol-2-phosphate*2 10 mM 
Dexamethasone*3 10 µM 
α MEM  
FBS 10ml/100ml 
Dexamethasone*1 1 M 
Insulin*2 10 µg/ml 
Indomethacin*3 120µM 
IBMX for induction 
No IBMX for culture 
0.5mM for 3 days 
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Neuroblast cell differentiation (33):   
  
  
  
  
*1Dimethylsulfoxid, Sigma Aldrich, Germany 
and 
 
 
 
 
 
 
Myocyte cell differentiation (27):   
 
 
 
*1PAN Biotech GmbH, Aidenbach, Germany 
*2Sigma Aldrich, Germany  
 
 
 
 
 
 
 
 
 
     DMEM  
FBS 2ml/100ml 
DMSO*1 1.25ml/100ml 
α MEM  
FBS 20ml/100ml 
β-Mercaptoethanol     1 mM/ml 
bFGF     5 ng/ml 
     DMEM  
Horse serum*1 10ml/100ml 
Azazytidine*2 for induction 1ml/100ml for 2 days 
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4.6 Staining 
In order to verify the differentiation process, the cells were stained for their 
specific cell line, after four to six weeks of culture as described above. 
 
4.6.1 Adipocytes 
Cells were washed in their culture dishes with PBS and later fixed in 4% 
formalin PBS solution for 30 minutes. After the formalin was removed, the 
cells were washed twice with distilled water and once with 60% Isopropanol in 
PBS, following application of the stain onto the cells: 50 mg Oil Red O (E. 
Merck (Schweiz) AG, Dietikon, Switzerland) were dissolved in 10 ml 100% 
Isopropanol. Then a working solution with a ratio of 3:2 stock solution:distilled 
water was prepared, from which was given onto the cells in their dishes. After 
10 minutes, the cells were rinsed once with 60% Isopropanol and twice with 
distilled water, before being visualized under the microscope (Carl Zeiss AG, 
Feldbach, Germany) for detection of adipocytes. 
 
4.6.2 Osteoblasts 
The cells were washed in their culture dishes with PBS, following fixation with 
4% formalin PBS solution for 30 minutes. After removal of the fixative, the 
dish was washed three times with distilled water, before Alizarin Red S stain 
(Fluka Chemie AG, Buchs, Switzerland) was applied onto the cells – 2% in 
water, pH 4.2 with 10% ammonium hydroxide. Incubation time was 10 
minutes, the stain was removed and the cells washed three times with 
distilled water and once with PBS. The cells then could be observed under 
the microscope, for detection of osteoblasts. 
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4.6.3 Endothelial cells 
The cultured cells were washed with PBS and fixed in 4% PFA/PBS solution 
for 10 minutes at room temperature. After removal of the fixative, the cells 
were washed another time in PBS, following a block with 0.1 M Glycine 
(Sigma Aldrich, Germany) in PBS for 5 minutes, before continuing with 
permeabilization in 0.2% Triton X100/PBS (Sigma Aldrich, Germany) for 10 
minutes. After washing with PBS, a block with 5% goat serum in 1% 
BSA/PBS was applied for 30 minutes. Incubation of the primary antibodies 
was done with Thrombomodulin (Dako, Zug, Switzerland), von-Willebrandt 
Factor (Sigma Aldrich, Germany) and Phalloidin (Alexa Fluor 488 Phalloidin, 
Invitrogen, Carlsbad, USA), each diluted in 5% goat serum in 1% BSA/PBS at 
concentrations of 1:50, 1:200 and 1:100 respectively, for 1 hour at room 
temperature. The cells were then washed and the secondary antibodies FITC 
(Fluorescein isothiocyanate conjugated, Sigma Aldrich, Germany) and Cy3 
(Cyanine dye, Jackson Immuno Research, West Grove, USA) were applied, 
in 1:100 and 1:200 dilutions respectively, incubating for 45 minutes at room 
temperature. Cells were then rinsed with PBS three times in their dishes and 
finally embedded in Lisbeth`s medium, containing 0.1 M Tris-HCL (pH 9.5) / 
glycerol (3:7) with 50 mg/ml n-propyl gallate as anti fading reagent (Donation 
from I. Agarkova, University Hospital Zurich, Switzerland). Finally the cells 
were inspected under the immunofluorescent microscope (Leica 
Microsystems AG, Herbrugg, Switzerland). 
(Part of the dish with the endothelial cells was separated and stained with the 
dyes used for myocytes, as negative control.) 
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4.6.4 Myocytes 
The cultured cells were washed with PBS and fixed in 4% PFA/PBS solution 
for 10 minutes at room temperature. After removal of the fixative, the cells 
were washed another time in PBS, following a block with 0.1 M Glycine in 
PBS for 5 minutes, before continuing with permeabilization in 0.2% Triton 
X100/PBS for 10 minutes. After washing with PBS, a block with 5% goat 
serum in 1% BSA/PBS is applied for 30 minutes. Incubation of the primary 
antibodies was done with α Actinin (Sigma Aldrich, Germany), EH-Myomesin 
(Donation from I. Agarkova, University Hospital Zurich, Switzerland) and 
Phalloidin (Alexa Fluor 488 Phalloidin, Invitrogen, Carlsbad, USA), each 
diluted in 5% goat serum in 1% BSA/PBS at concentrations of 1:500, 1:1000 
and 1:100 respectively, for 1 hour at room temperature. The cells were then 
washed and the secondary antibodies FITC and Cy3 were applied, in 1:100 
and 1:200 dilutions respectively, incubating for 45 minutes at room 
temperature. Cells were then rinsed with PBS three times in their dishes and 
finally embedded in Lisbeth`s medium, containing 0.1 M Tris-HCL (pH 9.5) / 
glycerol (3:7) with 50 mg/ml n-propyl gallate as anti fading reagent. Finally 
the cells were inspected under the immunofluorescent microscope. 
(Part of the dish with the myocyte cells was separated and stained with the 
dyes used for endothelial cells, as negative control.) 
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5 Results 
 
5.1 Isolation 
In the first attempts 0.5 mg/ml collagenase were used to digest the testis 
tissue obtained through orchiectomy, showing no dissociation of the tissue. In 
further trials the concentration of the digestive solution was increased to        
2 mg/ml collagenase, resulting in scattered dissociation of single cells, which 
blocked up when used in the syringes for the following MACS sorting. At last 
a final working concentration of 20 mg/ml collagenase caused the connective 
tissue to be digested for the most part and there was no clot formation after 
centrifugation of the cells suspension. The so obtained cells were free from 
other debris, large in number and could be used in MACS syringes for sorting 
(Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Cells after tissue digestion with collagenase 
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5.2 MACS – Magnetically Activated Cell Sorting 
The numbers of cells obtained through the MACS for CD 90 positive antibody 
are shown in Figure 2, ranging from approx 300.000 to approx. 2.000.000 per 
testis tissue sample, in average approx. 1.170.000 cells per testis tissue 
sample (n=5), irrespective of the size of the sample, i.e. ectomy or biopsy. 
 
Patient # Patients’ Age 
(Years) 
No. of cells isolated after 
CD 90 MACS 
6 83 440.000 
4 77 300.000 
5 58 1.640.000 
3 55 1.480.000 
7 21 1.980.000 
 
Figure 2: Table showing the number of cells isolated in selected patients 
 
Further antibodies such as CD 49f and CD 29 were explored with 
magnetically activated cell sorting. The results for CD 49f showed an isolation 
number ranging from 200.000 to 1.500.000, in average 810.000 cells per 
testis tissue sample (n=5) and for CD 29 from 350.000 to 1.000.000, in 
average 670.000 cells per testis tissue sample (n=5). 
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5.3 FACS – Fluorescent Activated Cell Sorting 
 
CD 49f analysis:  
In the side scatter diagram of the FACS analysis it could be seen that two cell 
populations were found in the cell suspension (Figure 3). The more dense 
and greater of these two was suspected to be the population containing CD 
49f positive cells (Figure 4). 
In another subpopulation (P4 in figure 4) the amount of parent cells is 20.7% 
(27.1 % CD 49f - 6.4 % control). Measured against the total number of cells, 
12.6% (17.1 % CD 49f – 4.5 % control) of the total cells may be assumed to 
be CD 49f positive. 
 
CD 29 analysis:  
In the side scatter diagram of the FACS analysis it could be seen that two cell 
populations were found in the cell suspension (Figure 5). The more dense 
and greater of these two was suspected to be the population containing CD 
29 positive cells (Figure 6).  
In another subpopulation (P4 in figure 6) the amount of parent cells is 7.7% 
(21.1 % CD 29 – 13.4 % control). Measured against the total number of cells, 
4.7% (13.6 % CD 29 – 8.9 % control) of the total cells may be assumed to be 
CD 29 positive. 
 
The average of all cell samples was as follows 
 
CD 49f positive selection  Ø Parent 18.6% 
     Ø Total 10.9% 
 
CD 29 positive selection  Ø Parent 5.7% 
     Ø Total 2.7% 
 - 27 -
FACS CD 49f 
 
 
 
 
 
 
 
 
 
Figure 3: Cell counts of all events        Figure 4: Cell counts of the greater                    
subpopulation extracted from all events 
 
 
 
FACS IgG2a Control 
 
 
 
 
 
 
 
 
 
Cell counts of all events              Cell counts of the greater 
subpopulation extracted from all events 
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FACS CD 29 
 
 
 
 
 
 
 
 
 
Figure 5: Cell counts of all events        Figure 6: Cell counts of the greater    
subpopulation extracted from all events 
 
 
 
FACS IgG1 Control 
 
 
 
 
 
 
 
 
 
Cell counts of all events        Cell counts of the greater
                      subpopulation extracted from all events 
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5.4 Culture 
 
In all samples investigated the number of cells critically diminished until 
absolute loss of all cells in less than two weeks, when the cells were kept in  
α MEM medium containing IGF 1.5 µg/100ml, GM 0.1 ml/100ml, bFGF 0.1 
µg/100ml, GDNF 0.4 µg/100ml. The cell number was in average reduced from 
initially 250.000 at the time of setting up the culture, to only 20.000 later one 
week, a drop of 92% (Figure 7 and 8). 
 
The DMEM containing media, supplemented only with GM 0.1 ml/100ml and 
FBS 10 ml/100ml showed a reduction from in average initially 250.000 at the 
time of setting up the culture, to as little as 88.000 cells, counted after one 
week. This resembles a decrease of 65% (Figure 7 and 8). 
 
When EBM-2 medium in combination with FBS 2ml/100ml, FGF 0.1 ml/100ml, 
EGF 0.1 ml/100ml, GM 0.1 ml/100ml, IGF 0.1 ml/100ml was used for 
maintenance of the adult testicular derived stem cells, the loss was found to 
be 43% in the first week, from initially 250.000 cells to 144.000 cells in 
average (Figure 7, 8 and 9). 
 
Different test series included the use of DMEM medium with no supplemented 
growth factor. This condition showed similar results.  
Another attempt was the use of EBM-2 medium in combination with the 
growth factors used with the α MEM medium; IGF, bFGF and GDNF. 
Furthermore the effects of the growth factor used in combination with EBM-2 
(FBS, FGF, EGF, IGF), DMEM (FBS) and α MEM (IGF, bFGF, GDNF) were 
investigated by combinations at different concentration than those already 
mentioned. However, in none of these alternative trials could the cells be 
maintained for longer than two weeks nor be expanded. 
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Although the mentioned loss was observed during the first two weeks, the 
cells exposed to the EBM-2 medium proliferated very effectively after this 
time and could be maintained for over five weeks. The proliferation rate was 
high, and the number of cells cell doubled every seven days. 
 
 
Patient 
# 
Patients’ 
Age 
(Years) 
No. of 
cells 
isolated 
after CD 
90 MACS 
Culture 
Medium  
No. of 
cells 
put in 
culture 
No. of 
cells 
after 7 
days 
No. of 
cells 
after 14 
days 
No. of 
cells 
after 21 
days 
No. of 
cells 
after 28 
days 
6 83 440.000 EBM 100.000 65.000 40.000 75.000 130.000 
   DMEM 100.000 40.000 15.000 5.000 - 
   α MEM 100.000 5.000 - - - 
5 58 1.640.000 EBM 400.000 220.000 150.000 240.000 400.000 
   DMEM 400.000 140.000 33.000 - - 
   α MEM 400.000 40.000 - - - 
3 55 1.480.000 EBM 300.000 130.000 150.000 200.000 345.000 
   DMEM 300.000 90.000 27.000 - - 
   α MEM 300.000 27.000 3.000 - - 
7 21 1.980.000 EBM 200.000 160.000 135.000 190.000 460.000 
   DMEM 200.000 80.000 20.000 4.000 - 
   α MEM 200.000 7.000 - - - 
 
Figure 7: Table showing cell numbers of selected cultures in the first 4 weeks 
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 EBM DMEM α MEM 
After 
1 
day 
   
After 
7 
days 
   
After 
21 
days 
   
After 
28 
days 
  
 
 
Figure 8: Cells cultured in EBM, DMEM and α MEM after 1, 7, 21 and 28 days 
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Figure 9: MACS CD 90 positive cells in EBM-2 medium after 19 days 
 
 
Two non-differentiated cell lines were frozen after the process of isolation and 
again thawed and differentiated later. The potential for differentiation was no 
different to that of cells before cryoconservation. 
However, cells that had already been differentiated and afterwards 
cryoconserved, showed only very little ability to multiply after defrosting and 
died within 10 days. 
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5.5 Differentiation and staining 
 
In one set of cell lines (n=5), the cells were exposed to the differentiation 
media, after one week of culture in EBM-2 medium, which was shown to be 
the most adequate condition for CD 90 positive testicular derived stem cells 
to be maintained. This was done, because the cells after isolation were only 
very little in number (approx. 980.000 cells). A control was conducted directly 
after isolation, with a fewer number of cells. It could thus be observed, that in 
an earlier point of differentiation, the potential of the cells might seem more 
effective, as the cells kept in the EBM-2 medium acquainted little 
morphological change. However, the number directly after isolation was very 
small and the cells did not proliferate when kept in the differentiating media, 
they only altered phenotypically. The cells on which the differentiation was 
induced after one week post isolation, differentiated into their destined cell 
type and their number was higher than those differentiated directly after 
isolation. 
 
In another set of cell lines (n=3), all of the isolated cells were induced to 
differentiate directly after isolation and magnetic sorting for CD 90 positive 
cells. The isolated cell number was very high (approx. 1.390.000 cells) and 
there was no need to expand the tissue prior to differentiation. 
The cells were kept to differentiate for five weeks and then analysed by 
staining. The culture of the cells showed no problems and in contrast to the 
previously described cell line, the cells proliferated at a high proliferation rate 
during differentiation, making it necessary to passage the cultures every 6 
days. 
(Figures 10-14) 
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Cells after 27 days of differentiation 
 
Figure 10: Control 
 
 
 
 
 
 
 
 
 
Figure 11: Myocytes                     Figure 12: Osteoblasts 
 
 
 
 
 
 
 
 
 
Figure 13: Adipocytes             Figure 14: Endothelial 
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The staining of the endothelial differentiating cell line showed an expression 
of Thrombomodulin, von-Willebrandt Factor and Phalloidin (Figure 16). In the 
immunofluorescent dyes of myocyte differentiating cell lines, α Actinin, EH-
Myomesin and Phalloidin could be demonstrated (Figure 15). 
The adipocyte cell lines successfully acquired the staining of the Oil Red O 
dye, while the osteoblast cell lines took on the Alizarin Red S stain, both 
being investigated under a phase contrast microscope. 
 
It needs to be mentioned, that the two earlier mentioned neurocyte 
differentiation media which had been used, provoked cell death after a few 
days.  
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Figure 15: Myocytes. Green: EH-Myomesin, Red: α Actinin, Blue: Phalloidin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Endothelial cells. Green: von-Willebrandt Factor, Red: 
Thrombomodulin, Blue: Phalloidin 
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6. Discussion 
6.1 Discussion of the results 
 
6.1.1 Isolation 
In the first attempts it was difficult to digest the testis tissue obtained by 
orchiectomy. Previous reports from mouse tissue digestion described to have 
used 0.5 mg/ml collagenase for dissociation of the connective tissue (1, 3, 6, 
11, 13, 17-21, 23).  
As this was not potent enough to generate enzymatic digestion of the tissue, 
2 mg/ml collagenase were used in the following isolations of the human testis 
tissue. With this the connective tissue was not sufficiently digested for the 
subsequent MACS sorting. Therefore only a small amount of purified cells 
could be isolated and sorted by the MACS. 
Small progresses were achieved by additionally exposing the cell suspension 
to trypsin 0.05% for 15 minutes. This made the reunion of the dissociated 
tissue in centrifugation less critical. 
Another option explored was to filter the tissue in order to separate tough 
connective tissue, from smaller cells. For this a 500 µm mash had been used, 
formed like a cone and fixed on a funnel. The filtered cell suspension could 
smoothly be used in the syringes for the following MACS analysis. 
The breakthrough was achieved, when 20 mg/ml collagenase was used. The 
connective tissue could for the most part be digested and there was no clot 
formation after centrifugation of the cells suspension.  
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6.1.2 MACS – Magnetically Activated Cell Sorting 
Provided the cell separation from the testis tissue was accomplished 
successfully, the MACS process itself showed no greater difficulties. 
In the first attempts the magnetically labelled antibody HLA-ABC was used, in 
reference to the hypothesis, that spermatogonial stem cells are part of the 
very rarely found HLA-ABC negative cells. However, this thesis could not be 
confirmed, as the amount of HLA-ABC negative cells and the HLA-ABC 
positive cells were almost identical. However, it should be well noted, that it 
was found, that the lack of HLA-ABC antibody on spermatogonial stem cells 
could be confirmed by FACS analysis (data not shown). 
Further antibodies such as CD 49f and CD 29 had been explored with 
magnetically activated cell sorting. However, the results could not prove to be 
superior to those of CD 90 (revealed through cell count). In the following 
sortings, this was set as the default antibody used for cell sorting.  The 
antibodies CD 49f and CD 29 were subsequently used for the fluorescent 
analysis of the sorted cells (FACS). 
 
Also a combination of HLA-ABC negative and CD 49f, CD 29 and CD 24 
positive cells was investigated in MACS analysis. The verification with FACS 
analysis however could not prove the sorting to have been successful. 
 
The cells obtained through the MACS for CD 90 positive antibody were very 
different in number, ranging from approx 300.000 to approx. 2.000.000 per 
testis tissue sample, irrespective of the size of the sample, i.e. ectomy or 
biopsy. 
The patients` age ranged from 21 to 83 and as age was rising, the 
concentration of obtained cells decreased dramatically (Figure 2). 
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6.1.3 FACS – Fluorescent Activated Cell Sorting 
The main focus was put upon the investigation of CD 90 positive cells, being 
sorted out prior to FACS by MACS. These cells were analysed for surface 
markers Integrin α6 (CD 29) and Integrin β1 (CD 49f), using IgG1 and IgG2A 
as controls respectively. The results proved that CD 49f and CD 29, both 
markers of pluripotent like stem cells, are co-expressed in the investigated 
cells and thus suggest that these cells exhibit stem cell like surface 
characteristics. 
 
6.1.4 Culture 
The investigations on which culture medium would be the most suitable to 
culture human adult derived spermatogonial stem cells showed, that the best 
results for maintenance and expansion of the CD 90 positive cells was to use 
EBM-2 culture medium with the corresponding growth factor supplements 
provided by the manufacturer.  
It should be mentioned, that although there was a significant loss observed 
during the first two weeks, the cells exposed to the EBM-2 medium 
proliferated very effectively after this time. Being cultured in the EBM-2 
medium, the cells could be maintained for over five weeks.  
 
6.1.5 Differentiation and staining 
The differentiation media used showed a successful differentiation of the 
spermatogonial adult stem cells into endothelial (Figure 16) and myocytes 
(Figure 13) cell line, as well as of the osteoblast (Figure 14) and adipocyte 
(Figure 15) differentiation. However not for neurocyte cells. 
The staining showed positive results for the endothelial differentiating cell 
line, as well as the myocytes in the immunofluorescent dyes. The adipocyte 
and osteoblast cell lines resembled positive results, being investigated under 
a phase contrast microscope after simple dye staining.  
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6.2 Discussion of the subject matter 
 
It could successfully be shown, that from human adult testicular tissue, cells 
can be isolated, which exhibit pluripotent stem cell like behaviour, i.e. are 
able to be differentiated into cell lines of different germ layers. It could be 
suggested, which culture supplements play a role in expansion of the cells, 
while maintaining their stem cell like potential. We could show that MACS 
selection with specific labelled antibodies is effective for first selection of the 
desired stem cells. 
 
Recent studies have primarily investigated the properties of adult 
spermatogonial stem cells in mouse and rat species and not human derived 
cells (1, 3, 5, 6, 10, 11, 13, 14, 17-21, 23, 25). Thus a limitation of this study 
is the lack of an established human control cell, to which this study could be 
referred to, especially because the definition of the term pluripotency 
incorporates different criteria in mouse and human stem cells.  
 
It was clearly experienced, that the potential of separation of the testis tissue 
and the differentiation of the isolated cells was very diverse, depending on 
the patients` age. The best results were acquired with a twenty-one year old 
patient, where no difficulties in the enzymatic digestion of the connective 
tissue were experienced and the differentiation potential of the stem cells was 
enormously stronger, than that of other samples.  
 
Related to this, the source of the tissue samples represents a debatable 
aspect. The obtained tissue sample were taken from two origins; orchiectomy 
in patients with metastasizing prostate cancer, or testis biopsies from patients 
with testicular torsion. It could be observed, that the latter, although much 
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smaller in size, provided a higher concentration of pluripotent cells, as well as 
a better quality in terms of potential to differentiate. 
It should be discussed, whether donation of cells for tissue engineering 
purpose could become a standard procedure of diagnostics in patients with 
testicular torsion, thus providing a potentially valuable source of these cells. 
However the feasibility for these biopsies should be further investigated. 
 
The question remains, whether expansion of the freshly isolated and not yet 
differentiated cells results in higher cell number, than cells being 
differentiated right after isolation and later being expanded. Again cells 
samples from older patients showed slightly different behaviour to those of 
younger age groups.  The cells from elder patients showed a lower rate of 
multiplication after differentiation after a short period of culture than before, 
where as the younger cells expanded quicker after the process of 
differentiation. 
 
Further exploration on what surface markers for magnetically activated cell 
sorting serve the most efficient results might seem needful. Antibodies such 
as CD 90, CD 49f and CD 29 all seem promising candidates, but lack 
quantitative characterisation of expression on human adult testis derived 
stem cells. 
A simultaneous isolation had been tried, but resulted in no exploitable data. A 
successive selection of the markers, following each other in multiple MACS 
passages could be shown to be a promising approach. 
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A heterogeneous culture of cells could be differentiated into cells of different 
germinal layers, thus suggesting a pluripotent potential among the cells. 
However to be certain of the potential of one specific cell to exhibit 
pluripotency, a single cell clone has to be obtained, cultured and 
differentiated.  
As a further step to achieve separation and culture of a single cell clone of 
pluripotent human adult testicular stem cells, attachment to specifically 
coated culture dishes (e.g. vimentin) or a broader selection of distinct surface 
markers, as indicated above could be tried. 
 
Endothelial staining proved to be positive for Thrombomodulin and Phalloidin, 
however only weakly for von-Willebrandt Factor. This suggests, that von-
Willebrandt Factor is only being expressed in a later stage of cell 
development. In future studies it should be analyzed with different stains, at 
what stage of differentiation of the cells, which cell-typical cell organelles are 
being formed, e.g. in myocytes. A promising method could be transmission 
electron microscopy. 
 
It has to be considered, that due to possible genetic change occurring while 
the cells are being cultured, the cells may turn into uncontrolled proliferation 
stages. One of the most critical points of controlling the potential and the time 
of differentiation of the stem cells, is the composition of the culture medium. 
Therefore strict monitoring of genetic alterations is a prerequisite to the re-
implantation of the human adult pluripotent stem cells in clinical practice. 
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6.3 Outlook 
 
The main goal of this study was to isolate human pluripotent stem cells from 
adult – non-embryonic - tissue and to investigate their usability for tissue 
engineering cell based therapies, presenting a  key step to the resolution of 
the ethical problem when working with allogenic embryonic stem cells. Recent 
studies have successfully demonstrated, that this can be conducted on adult 
testis of mice and rats (1, 3, 5, 6, 10, 11, 13, 14, 17-21, 23, 25).  
 
It could be shown, that in patients from which only a testicular biopsy had 
been gained, the young age made it possible, that from this minute mass real 
tissue engineered textures could be generated. Taken this into account, it 
shall be investigated, whether this could be sufficient enough even for elderly 
patients, with no therapeutic need of orchiectomy. 
 
Also the concentration of cells gained through MACS sorting still serves the 
chance to increase. If the proper combination of antibodies has been 
declared, the chances for developing well functioning differentiated cells are 
very good. 
 
Starting from the isolation of the tissue, the enzymatic digestion should be 
improved, especially with the fibrous connective tissue in elderly patients. 
Many cells degenerate in the processing with enzymes and are mechanically 
harmed through the magnetic sorting cells sorting process and passaging 
cultures. The next step should be isolation with lower rates of centrifugation 
and to omit trypsin for passaging, using only tools of cell-specific attachment 
for subculturing. 
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The most critical improvements which need to be done are higher 
concentrations in isolating and sorting the cells from the testis tissue, 
procedures of resecting only ultimately small testis tissue samples from 
biopsies and a greater rate of expansion of the cells while maintaining their 
pluripotent potential to differentiate. 
 
After all, this data suggests the potential of a population of so named 
pluripotent like stem cells in human adult testicular tissue and might be a 
crucial piece to the solution to cell based autologous regenerative medicine 
and tissue engineering. 
 
 
At last it should be mentioned, that recently a group of researcher around 
Skutella et al. published the discovery of pluripotent human adult testicular 
derived stem cells (34). Their investigations were based on MACS isolation of 
the cells and evidence of pluripotency through formation of teratoma, cell line 
differentiation into all three germ layers and demonstration of specific marker-
genes. 
This paper has now been strongly discussed among stem cell researchers, as 
the analytic proof does not seem substantiated and fully convincing to term 
the declared all-rounder cells “truly pluripotent”. 
 
 
 
 
 
 
 
 
 - 45 -
7 References 
Markers: 
1. T Shinohara, M R Avarbock, und R L Brinster, “beta1- and alpha6-
integrin are surface markers on mouse spermatogonial stem cells,” 
Proceedings of the National Academy of Sciences of the United States 
of America 96, no. 10 (Mai 11, 1999): 5504-5509.   
2. Lucio Barile u. a., “Cardiac stem cells: isolation, expansion and 
experimental use for myocardial regeneration,” Nature Clinical 
Practice. Cardiovascular Medicine 4 Suppl 1 (Februar 2007): S9-S14.   
3. Mito Kanatsu-Shinohara, Shinya Toyokuni, und Takashi Shinohara, 
“CD9 is a surface marker on mouse and rat male germline stem cells,” 
Biology of Reproduction 70, no. 1 (Januar 2004): 70-75.   
4. Jin Gyoung Jung u. a., “Development of novel markers for the 
characterization of chicken primordial germ cells,” Stem Cells (Dayton, 
Ohio) 23, no. 5 (Mai 2005): 689-698.   
5. Candace L Kerr u. a., “Expression of pluripotent stem cell markers in 
the human fetal testis,” Stem Cells (Dayton, Ohio) 26, no. 2 (Februar 
2008): 412-421.   
6. Marco Seandel u. a., “Generation of functional multipotent adult stem 
cells from GPR125+ germline progenitors,” Nature 449, no. 7160 
(September 20, 2007): 346-350.   
7. Yanfeng Li u. a., “[Immunomagnetic beads sorting and functional 
identification of human spermatogonial stem cells],” Zhonghua Nan Ke 
Xue = National Journal of Andrology 10, no. 8 (August 2004): 567-571.  
8. Nina Kossack u. a., “Isolation and characterization of pluripotent 
human spermatogonial stem cell-derived cells,” Stem Cells (Dayton, 
Ohio) 27, no. 1 (Januar 2009): 138-149.   
 - 46 -
9. M Dominici u. a., “Minimal criteria for defining multipotent 
mesenchymal stromal cells. The International Society for Cellular 
Therapy position statement,” Cytotherapy 8, no. 4 (2006): 315-317.   
10. Marco Seandel u. a., “Niche players: spermatogonial progenitors 
marked by GPR125,” Cell Cycle (Georgetown, Tex.) 7, no. 2 (Januar 
15, 2008): 135-140.   
11. Kaomei Guan u. a., “Pluripotency of spermatogonial stem cells from 
adult mouse testis,” Nature 440, no. 7088 (April 27, 2006): 1199-1203.  
12. Nady Golestaneh u. a., “Pluripotent Stem Cells Derived from Adult 
Human Testes,” Stem Cells and Development (März 12, 2009). 
13. Hiroshi Kubota, Mary R Avarbock, und Ralph L Brinster, 
“Spermatogonial stem cells share some, but not all, phenotypic and 
functional characteristics with other stem cells,” Proceedings of the 
National Academy of Sciences of the United States of America 100, no. 
11 (Mai 27, 2003): 6487-6492.   
14. Pedro M Aponte u. a., “Spermatogonial stem cells: characteristics and 
experimental possibilities,” APMIS: Acta Pathologica, Microbiologica, 
Et Immunologica Scandinavica 113, no. 11-12 (Dezember 2005): 727-
742.   
15. Yong Zhao, Honglan Wang, und Theodore Mazzone, “Identification of 
stem cells from human umbilical cord blood with embryonic and 
hematopoietic characteristics,” Experimental Cell Research 312, no. 13 
(August 1, 2006): 2454-2464.   
16. Jin Gyoung Jung u. a., “Identification, culture, and characterization of 
germline stem cell-like cells in chicken testes,” Biology of Reproduction 
76, no. 1 (Januar 2007): 173-182.   
 
 
 
 - 47 -
Culture: 
17. Hiroshi Kubota, Mary R Avarbock, und Ralph L Brinster, “Culture 
conditions and single growth factors affect fate determination of mouse 
spermatogonial stem cells,” Biology of Reproduction 71, no. 3 
(September 2004): 722-731.   
18. M Nagano u. a., “Culture of mouse spermatogonial stem cells,” Tissue 
& Cell 30, no. 4 (August 1998): 389-397.   
19. Hiroshi Kubota, Mary R Avarbock, und Ralph L Brinster, “Growth 
factors essential for self-renewal and expansion of mouse 
spermatogonial stem cells,” Proceedings of the National Academy of 
Sciences of the United States of America 101, no. 47 (November 23, 
2004): 16489-16494.   
20. Dongkee Jeong, Derek J McLean, und Michael D Griswold, “Long-term 
culture and transplantation of murine testicular germ cells,” Journal of 
Andrology 24, no. 5 (Oktober 2003): 661-669.   
21. Mito Kanatsu-Shinohara u. a., “Long-term proliferation in culture and 
germline transmission of mouse male germline stem cells,” Biology of 
Reproduction 69, no. 2 (August 2003): 612-616.   
22. Yan-feng Li u. a., “[Long-term survival of human spermatogonial stem 
cells in vitro and its functional identification],” Zhonghua Nan Ke Xue = 
National Journal of Andrology 11, no. 12 (Dezember 2005): 886-890, 
894.   
23. Makoto Nagano u. a., “Maintenance of mouse male germ line stem 
cells in vitro,” Biology of Reproduction 68, no. 6 (Juni 2003): 2207-
2214.   
24. Yan-feng Li u. a., “[Preliminary screening of specific surface markers of 
human spermatogonial stem cells],” Zhonghua Nan Ke Xue = National 
Journal of Andrology 11, no. 7 (Juli 2005): 486-489.   
 - 48 -
25. Pedro M Aponte u. a., “Spermatogonial stem cells: characteristics and 
experimental possibilities,” APMIS: Acta Pathologica, Microbiologica, 
Et Immunologica Scandinavica 113, no. 11-12 (Dezember 2005): 727-
742.   
 
 
Differentiation: 
26. Dörthe Schmidt u. a., “Cryopreserved amniotic fluid-derived cells: a 
lifelong autologous fetal stem cell source for heart valve tissue 
engineering,” The Journal of Heart Valve Disease 17, no. 4 (Juli 2008): 
446-455; discussion 455.   
27. Paolo De Coppi u. a., “Isolation of amniotic stem cell lines with 
potential for therapy,” Nature Biotechnology 25, no. 1 (Januar 2007): 
100-106.   
28. V. A. Maltsev u. a., “Embryonic stem cells differentiate in vitro into 
cardiomyocytes representing sinusnodal, atrial and ventricular cell 
types,” Mech. Dev. 44 (1993): 41-50.   
29. Kehat, “Development of cardiomyocytes from human ES cells,” 
Methods Enzymol. 365 (2003): 461-473.   
30. R. C. Bielby u. a., “In vitro differentiation and in vivo mineralization of 
osteogenic cells derived from human embryonic stem cells,” Tissue 
Eng. 10 (2004): 1518-1525.   
31. M. Bibel, “Differentiation of mouse embryonic stem cells into a defined 
neuronal lineage,” Nature Neurosci. 7 (2004): 1003-1009.   
32. J. Ringe, T. Haupl, und M. Sittinger, “Mesenchymal stem cells for 
tissue engineering of bone and cartilage,” Med. Klin. 98 (2003): 35-40.  
33. A. Prusa u.a., “Neurogenic cells in human amniotic fluid,” Am J Obstet 
Gynecol. 191 no. 1 (Jul 2004): 309-14. 
 
 - 49 -
Furthermore: 
34. Skutella et al., “Generation of pluripotent stem cells from adult human 
testis,” Nature (2008) 456(7720):344-9. 
 S. M. Pollard u. a., “Adherent neural stem (NS) cells from fetal and 
adult forebrain,” Cereb. Cortex 16 (2006): i112-i120.   
 Jingli Cai u. a., “Assessing self-renewal and differentiation in human 
embryonic stem cell lines,” Stem Cells (Dayton, Ohio) 24, no. 3 (März 
2006): 516-530.   
 C. T. Wittwer, G. C. Fillmore, und D. R. Hillyard, “Automated 
polymerase chain reaction in capillary tubes with hot air,” Nucleic Acids 
Res. 17 (1989): 4353-4357.   
 T. Shinohara, M. R. Avarbock, und R. L. Brinster, “[bgr]1- and [agr]6-
integrin are surface markers on mouse spermatogonial stem cells,” 
Proc. Natl Acad. Sci. USA 96 (1999): 5504-5509.   
 Derek J McLean u. a., “Characterization of spermatogonial stem cell 
maturation and differentiation in neonatal mice,” Biology of 
Reproduction 69, no. 6 (Dezember 2003): 2085-2091.   
 Brian P Hermann u. a., “Characterization, cryopreservation, and 
ablation of spermatogonial stem cells in adult rhesus macaques,” Stem 
Cells (Dayton, Ohio) 25, no. 9 (September 2007): 2330-2338.   
 J. B. Stukenborg, “Co-culture of spermatogonia with somatic cells in a 
novel three-dimensional soft-agar-culture-system,” J. Androl. 29 
(2007): 312-329.   
 G. Schatten u. a., “Culture of human embryonic stem cells,” Nature 
Methods 2 (2005): 455-463.   
 F. K. Hamra, “Defining the spermatogonial stem cell,” Dev. Biol. 269 
(2004):393-410.   
 
 - 50 -
 M J Shamblott u. a., “Derivation of pluripotent stem cells from cultured 
human primordial germ cells,” Proceedings of the National Academy of 
Sciences of the United States of America 95, no. 23 (November 10, 
1998): 13726-13731.   
 Y. Matsui, K. Zsebo, und B. L. Hogan, “Derivation of pluripotential 
embryonic stem cells from murine primordial germ cells in culture,” Cell 
70 (1992): 841-847.   
 Ginis, “Differences between human and mouse embryonic stem cells,” 
Dev. Biol. 269 (2004): 360-380.   
 N. Lumelsky, “Differentiation of embryonic stem cells to insulin-
secreting structures similar to pancreatic islets,” Science 292 (2001): 
1389-1394.   
 H. Segev u. a., “Differentiation of human embryonic stem cells into 
insulin-producing clusters,” Stem Cells 22 (2004): 265-274.   
 Meissner, M. Wernig, und R. Jaenisch, “Direct reprogramming of 
genetically unmodified fibroblasts into pluripotent stem cells,” Nature 
Biotechnol. 25 (2007): 1177-1181.   
 P. Blyszczuk, “Embryonic stem cells differentiate into insulin-producing 
cells without selection of nestin-expressing cells,” Int. J. Dev. Biol. 48 
(2004): 1095-1104.   
 J. A. Costoya, “Essential role of Plzf in maintenance of spermatogonial 
stem cells,” Nature Genet. 36 (2004): 653-659.   
 L. Turnpenny, “Evaluating human embryonic germ cells: concord and 
conflict as pluripotent stem cells,” Stem Cells 24 (2006): 212-220.   
 Mark S Fox u. a., “Feasibility of global gene expression analysis in 
testicular biopsies from infertile men,” Molecular Reproduction and 
Development 66, no. 4 (Dezember 2003): 403-421.   
 - 51 -
 Li-Xin Feng u. a., “Generation and in vitro differentiation of a 
spermatogonial cell line,” Science (New York, N.Y.) 297, no. 5580 (Juli 
19, 2002): 392-395.   
 Marco Seandel u. a., “Generation of functional multipotent adult stem 
cells from GPR125+ germline progenitors,” Nature 449, no. 7160 
(September 20, 2007): 346-350.   
 K. Okita, T. Ichisaka, und S. Yamanaka, “Generation of germline-
competent induced pluripotent stem cells,” Nature 448 (2007): 313-
317.   
 Mito Kanatsu-Shinohara u. a., “Generation of pluripotent stem cells 
from neonatal mouse testis,” Cell 119, no. 7 (Dezember 29, 2004): 
1001-1012.   
 Ralph L Brinster, “Germline stem cell transplantation and 
transgenesis,” Science (New York, N.Y.) 296, no. 5576 (Juni 21, 2002): 
2174-2176.   
 R. L. Brinster und M. R. Avarbock, “Germline transmission of donor 
haplotype following spermatogonial transplantation,” Proc. Natl Acad. 
Sci. USA 91 (1994): 11303-11307.   
 M J Shamblott u. a., “Human embryonic germ cell derivatives express a 
broad range of developmentally distinct markers and proliferate 
extensively in vitro,” Proceedings of the National Academy of Sciences 
of the United States of America 98, no. 1 (Januar 2, 2001): 113-118.   
 Jon M Oatley u. a., “Identifying genes important for spermatogonial 
stem cell self-renewal and survival,” Proceedings of the National 
Academy of Sciences of the United States of America 103, no. 25 (Juni 
20, 2006): 9524-9529.   
 M. Wernig, “In vitro reprogramming of fibroblasts into a pluripotent ES-
cell-like state,” Nature 448 (2007): 318-324.   
 - 52 -
 J. Yu, “Induced pluripotent stem cell lines derived from human somatic 
cells,” Science 318 (2007): 1917-1920. 
 G R Martin, “Isolation of a pluripotent cell line from early mouse 
embryos cultured in medium conditioned by teratocarcinoma stem 
cells,” Proceedings of the National Academy of Sciences of the United 
States of America 78, no. 12 (Dezember 1981): 7634-7638.   
 Marie-Claude Hofmann, Laura Braydich-Stolle, und Martin Dym, 
“Isolation of male germ-line stem cells; influence of GDNF,” 
Developmental Biology 279, no. 1 (März 1, 2005): 114-124.   
 M. Kanatsu-Shinohara, “Leukemia inhibitory factor enhances formation 
of germ cell colonies in neonatal mouse testis culture,” Biol. Reprod. 76 
(2007): 55-62.   
 J. L. Resnick u. a., “Long-term proliferation of mouse primordial germ 
cells in culture,” Nature 359 (1992): 550-551.   
 Ian Chambers u. a., “Nanog safeguards pluripotency and mediates 
germline development,” Nature 450, no. 7173 (Dezember 20, 2007): 
1230-1234.   
 Kaomei Guan u. a., “Pluripotency of spermatogonial stem cells from 
adult mouse testis,” Nature 440, no. 7088 (April 27, 2006): 1199-1203.  
 G Durcova-Hills, J Ainscough, und A McLaren, “Pluripotential stem 
cells derived from migrating primordial germ cells,” Differentiation; 
Research in Biological Diversity 68, no. 4-5 (Oktober 2001): 220-226.   
 D. G. de Rooij, “Rapid expansion of the spermatogonial stem cell tool 
box,” Proc. Natl Acad. Sci. USA 103 (2006): 7939-7940.   
 X Meng u. a., “Regulation of cell fate decision of undifferentiated 
spermatogonia by GDNF,” Science (New York, N.Y.) 287, no. 5457 
(Februar 25, 2000): 1489-1493.   
 H. Park, “Reprogramming of human somatic cells to pluripotency with 
defined factors,” Nature 451 (2008): 141-146.   
 - 53 -
 Martin Evans und Susan Hunter, “Source and nature of embryonic 
stem cells,” Comptes Rendus Biologies 325, no. 10 (Oktober 2002): 
1003-1007.   
 L. C. Stevens, “Spontaneous and experimentally induced testicular 
teratomas in mice,” Cell Differ. 15 (1984): 69-74.   
 Amander T Clark u. a., “Spontaneous differentiation of germ cells from 
human embryonic stem cells in vitro,” Human Molecular Genetics 13, 
no. 7 (April 1, 2004): 727-739.   
 Karim Nayernia, “Stem cells derived from testis show promise for 
treating a wide variety of medical conditions,” Cell Research 17, no. 11 
(November 2007): 895-897.   
 Hiroshi Kubota und Ralph L Brinster, “Technology insight: In vitro 
culture of spermatogonial stem cells and their potential therapeutic 
uses,” Nature Clinical Practice. Endocrinology & Metabolism 2, no. 2 
(Februar 2006): 99-108.   
 A D CHIQUOINE, “The identification, origin, and migration of the 
primordial germ cells in the mouse embryo,” The Anatomical Record 
118, no. 2 (Februar 1954): 135-146.   
 D. Alexander, “Transcription factor Egr-1 activates collagen expression 
in immortalized fibroblasts or fibrosarcoma cells,” Biol. Chem. 383 
(2002): 1845-1853.   
 Peter J Donovan und Maria P de Miguel, “Turning germ cells into stem 
cells,” Current Opinion in Genetics & Development 13, no. 5 (Oktober 
2003): 463-471.   
 
 
 
 
 
 - 54 -
8 Acknowledgements 
 
I should like to express my special gratitude to Prof. Dr. Dr. Simon P. 
Hoerstrup, for offering me this valuable opportunity of working in the fields of 
tissue engineering under his professional guidance and always being 
disposable for questions. 
My warm thanks go out to Dr. Dr. Dörthe Schmidt, for supervising me 
throughout this project and teaching me the fundamental skills. 
Furthermore I thank Dr. Hubert John, for supplying the biopsies and Roman 
Schönauer for sharing his skills with me. 
Special thanks to Irina Agarkova, Chad Brokopp, Michael Bullen, Jan-Karl 
Burkhardt, Sandra Edwin, Marion Fischer, Annika Levandowski, and Armin 
Zürcher, 
my parents Cherokee and Uwe, my sisters Jasmin and Vanessa and my 
grandparents, 
as well as Arline Reiner, Ms. Lourens and everybody who supported me 
throughout this intensive work. 
 
I dedicate this work to the advancement of sciences and hope to contribute to 
the indispensable progress in medical treatment. 
 
 
 
 
 
 
 
 
Zurich, October 2007 – September 2010 
 - 55 -
9 Curriculum Vitae  
Pascal Alexander Heye aus Fürstentum Liechtenstein 
 
Personal information 
Name:    Pascal Alexander Heye 
Date and place of birth: 14.03.1986, Rabat, Morocco 
Nationality:    Fürstentum Liechtenstein 
 
University Education 
11 / 2011   Medical State Examination 
    “Eidgenössische Prüfung Humanmedizin” 
    Medical Faculty of the University of Zurich, Switzerland 
 
2007 – 2011   Medical Faculty of the University of Zurich, Switzerland 
    Course of Medical Studies 
2005 - 2007   Medical Faculty of the University of Szeged, Hungary  
Course of Medical Studies 
English Program 
 
School Education 
2004 - 2005    German School Budapest, sec. school, Hungary 
    - German Senior Certificate 
1998 - 2003    German School Pretoria, sec. school, South Africa 
- South African Senior Certificate 
1996 - 1998    Nikolaus Cusanus Gymnasium, Bonn, Germany 
1994 - 1996    Gotenschule, Bonn, Germany 
1992 - 1994    German School Copenhagen, Denmark 
 
